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Abstract
Rubinstein-Taybi syndrome (RTS) is a rare developmental disorder characterized by craniofacial dysmorphisms, broad thumbs 
and toes, mental and growth deficiency, and recurrent respiratory infections. RTS has been associated with CREBBP gene 
mutations, but EP300 gene mutations have recently been reported in 6 individuals. In the present study, the humoral immune 
response in 16 RTS patients with recurrent respiratory infections of possible bacterial etiology was evaluated. No significant 
differences between patients and 16 healthy controls were detected to explain the high susceptibility to respiratory infections: 
normal or elevated serum immunoglobulin levels, normal salivary IgA levels, and a good antibody response to both polysac-
charide and protein antigens were observed. However, most patients presented high serum IgM levels, a high number of total 
B cell and B subsets, and also high percentiles of apoptosis, suggesting that they could present B dysregulation. The CREBBP/
p300 family gene is extremely important for B-cell regulation, and RTS may represent an interesting human model for studying 
the molecular mechanisms involved in B-cell development.
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Rubinstein-Taybi syndrome (RTS), a clinically well-
defined condition, is a rare developmental disorder char-
acterized by craniofacial dysmorphisms, broad thumbs and 
toes, and mental and growth deficiency (1). The prevalence 
at birth is estimated to be 1 in 125,000 liveborn infants (2). 
RTS usually occurs sporadically although it may be inherited 
as an autosomal dominant disorder (OMIM 180849) (2,3). 
The diagnosis is still essentially clinical and has been based 
on characteristic features (3). The major items to look for 
in RTS are a beaked nose, grimacing smile, broad thumbs 
and big toes, and mental retardation (4). The main clinical 
problems are failure to thrive, congenital heart defects, and 
recurrent respiratory infections (5). RTS has been associ-
ated with mutations of the CREB-binding protein (CREBBP 
or CBP) gene, located on chromosome 16p13.3 (6), which 
have been demonstrated in 45-56% of RTS patients (7). 
However, mutations of the EP300 (p300) gene, located on 
chromosome 22q13.3, were recently identified in six RTS 
patients (8,9). 
A review of 571 RTS cases has demonstrated elevated 
susceptibility to infections during infancy and childhood (5). 
The natural course of the disease shows that morbidity is 
mainly determined by recurrent respiratory infections that 
were initially attributed to microaspirations consequent to 
gastroesophageal reflux disease (1,5). However, some 
investigators have suspected the existence of primary im-
munodeficiency affected by RTS (10,11). 
Ming et al. (12) performed a review of 65 genetic dis-
eases that showed increased susceptibility to infections, 
and immune disorders were identified in many of them. This 
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review showed that most genetic diseases were concomitant 
with primary immunodeficiency and RTS was included as a 
syndrome associated with phagocytic immunodeficiency. 
Immunological evaluation of a 4-year-old RTS patient 
who presented suppurative otitis media and purulent rhinitis 
during the first years of life revealed low numbers of T and 
B cells and low levels of IgM and IgG antibodies to poly-
saccharide antigens. High serum levels of IgA antibodies, 
normal levels of IgG subclasses (IgG1, IgG2, IgG3, and 
IgG4) failed to respond to the Pneumovax vaccine (11). A 
Brazilian RTS patient with gum inflammation and bleeding 
was subjected to study of dental aspects (13). Addition-
ally, this patient had recurrent respiratory infections in the 
first decade of life. Therefore, the authors conducted an 
immunological screening, which revealed normal levels 
of serum IgG and IgA antibodies, high IgM levels, normal 
anti-tetanus IgG levels, normal absolute values of total 
leukocytes in peripheral blood, and of lymphocytes, neu-
trophils, basophils, eosinophils and monocytes, as well 
as normal percentages of T CD4+ and T CD8+ cells (13). 
However, despite the high susceptibility of RTS patients to 
recurrent infections, there have been few reports about the 
evaluation of their immunocompetence (10,11). 
In the present paper, we report the results of an evalu-
ation of the humoral immune response of 16 Brazilian RTS 
patients with recurrent respiratory infections. Taken together, 
the data obtained in this study suggest that RTS patients 
present B-cell dysregulation.
Patients and Methods
The diagnosis of RTS was first established by a pedi-
atric geneticist using only clinical criteria (3). We studied 
a cohort of 16 unrelated RTS patients (4 males and 12 
females, age range: 2-24 years). The study group consisted 
of children, adolescents and young adults with unequivocal 
RTS, defined here by the presence of the following four 
major clinical signs: short stature, typical facies, skeletal 
abnormalities, and mild to moderate mental retardation. 
The main features that allow a diagnosis of RTS are to be 
found in the face and limbs. 
Figure 1 shows some clinical signs of one 23-year-old 
RTS patient. The facial appearance is striking: bushy and 
arched eyebrows, long eyelashes, downslanting palpebral 
fissures, broad nasal brigde, beaked nose with the nasal 
septum extending downwards, and grimacing smile (see 
Figure 1A,B). Broad thumbs and broad big toes are pres-
ent in almost all cases. Thumbs and halluces are radially 
deviated in most patients (see Figure 1C,D). 
Fifteen of our RTS patients had a normal karyotype at 
450+ band resolution, except patient 2, who presented a de 
novo reciprocal translocation t(2;16) (q36.3; p13.3) (14).
An additional criterion adopted for inclusion in this im-
munological study was the presence of recurrent infections. 
All patients presented recurrent respiratory infections in 
the first decade of life, as well as urinary tract infections 
(see Table 1). The patients had five or more episodes of 
recurrent respiratory infections per year in the first decade 
of life, and other clinical findings. Our RTS patients showed 
some of the 10 warning signs for the investigation of primary 
immunodeficiency in children, as described by the Brazil-
ian Group for Immunodeficiency Disease - BRAGID (www.
imunopediatria.org.br). We did not observe abnormally 
enlarged lymph nodes or splenomegaly in our RTS patients. 
There was no consanguinity in any family. The clinical and 
laboratory protocols were approved by the Ethics Commit-
tee for Analysis of Research Projects of the Hospital da 
Clínicas da Faculdade de Medicina da Universidade de 
São Paulo according to the Brazilian Ministry of Health’s 
Regulatory Guidelines (Resolution 196/96 of the National 
Council of Health). The parents of the RTS patients and 
16 healthy controls signed an informed consent form prior 
to inclusion in the study.
Antibody determinations 
Serum levels of total IgG, IgM, IgA, and IgG subclasses 
were determined by single radial immunodiffusion using a 
monoclonal antibody (mAb) obtained from Sigma-Aldrich, 
USA: clone I1011 for IgG, clone I1261 for IgA, and clone 
I8260 for IgM. For the IgG subclasses we used an mAb 
Figure 1. A, Patient 13 at the age of 23 years. Note sloping fore-
head, downslanting palpebral fissures, broad nasal bridge, and 
beaked nose with the nasal septum extending well below. B, Gri-
macing smile and congenital kyphosis. C,D, Hands and feet of 
patient 13. Note that thumbs and halluces are radially deviated. 
C, Note the broad thumbs and D, broad halluces. Informed con-
sent was obtained for publication of this figure.
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obtained from Unipath, UK: clone JL512 for IgG1, clone 
Gom1 for IgG2, clone ZG4 for IgG3, and clone GB7B for 
IgG4. The results were compared to those for a group of 
330 Brazilian age-matched controls (15). We also deter-
mined salivary IgA levels in 9 patients using an ELISA 
technique with an mAb from Sigma-Aldrich, clone I0884. 
Samples of unstimulated whole saliva were obtained from 
9 RTS patients. 
The production of IgG antibodies against protein and 
polysaccharide antigens was evaluated in all patients for 
the tetanus toxoid and for the pneumococcal polysaccharide 
vaccine antigens, respectively. Patients were vaccinated 
with the 23-valent pneumococcal polysaccharide vaccine 
(Pneumo23®, Aventis Pasteur, France) and blood samples 
were collected before and 4 weeks after immunization. Anti-
pneumococcal IgG antibodies against serotypes 1, 3, 4, 5, 6B, 
9V, 14, 18C, 19F, and 23F (ATCC, USA) and IgM antibodies 
against pneumococcal serotypes 1, 3, 6B, 9V, and 14 (ATCC) 
were determined using a modified ELISA protocol (16,17). 
An adequate response to an individual polysaccharide was 
arbitrarily defined as a post-immunization antibody concentra-
tion equal to or higher than 1.3 mg/mL or a minimum 4-fold 
increase over the baseline value (16,17).
All patients with RTS had received the tetanus toxoid 
vaccine according to the schedule recommended by 
the Brazilian Ministry of Health. Anti-tetanus toxoid IgG 
antibodies present in serum samples from RTS patients 
were measured by ELISA using tetanus toxoid as antigen 
(Butantan Institute, São Paulo, SP, Brazil). The antibodies 
against protein-tetanus toxoid are T cell dependent and 
antibodies against carbohydrates are T cell independent.
Serum IgM antibody titers for the ABO group (isohemag-
glutinin) were measured by the agglutination technique using 
the Referencells-4 kit (Immucor, Belgium). The isohemag-
glutinins are natural antibodies of the IgM class, i.e., they 
are produced without stimulation.
Determination of absolute number of B cells and 
B-cell subtypes 
We also carried out immunophenotyping of blood lym-
phocyte samples using a FACSCalibur Becton Dickinson 
(BD, USA) flow cytometer at 488 nm, and cell surface 
markers for human leukocytes. Peripheral blood samples 
were double or triple marked with anti-human mAb from 
Biosciences Pharmingen (USA): anti-CD45-PECy5 (clone 
HI30), anti-CD20-FITC (clone 2H7), anti-CD27-PE (clone 
MT271), anti-CD5-PECy5 (clone UCHT2), anti-IgM-PE 
(clone G20-127), or isotype control antibodies. All stained 
cells were analyzed with a FACSCAN flow cytometer using 
the Cellquest software (BD). The results were compared 
to those obtained with peripheral blood samples from 14 
healthy adolescents and young adults. 
Apoptosis assay 
Apoptotic cells were measured in peripheral blood 
samples of 11 RTS patients and 11 healthy controls by flow 
cytometry after staining with annexin V-FITC and propidium 
iodide-PE using an apoptosis detection kit (BD) according to 
Table 1. Main clinical findings of the 16 Brazilian patients with Rubinstein-Taybi syndrome. 
Patients Gender Age (years) Ethnic background Recurrent respiratory 
infections
Other clinical 
findings
 1 Female 23.0 Caucasian 1 12
 2 Female 21.9 Caucasian 1 5
 3 Male 21.2 African and Caucasian 1, 2, 3, 4 9, 12
 4 Female 14.1 Caucasian 1, 2, 3, 4 7, 8, 9, 12, 14
 5 Female 12.8 Caucasian none 12
 6 Male 11.4 Caucasian 1, 3 6, 10
 7 Female 8.7 Caucasian 1, 3, 4 10
 8 Female 8.3 Caucasian 2, 4 10
 9 Female 12.1 Caucasian 1, 2, 3, 4 7, 8, 9
10 Female 7.3 Caucasian 2, 3, 4 8, 9
11 Female 6.6 Caucasian 2, 3 9
12 Female 3.4 Caucasian 1 11, 13
13 Female 23.0 African and Caucasian 1, 3 none
14 Male 12.8 Caucasian 1, 2 9, 10
15 Male 20.2 Caucasian 2, 4 12
16 Male 2.3 African and Caucasian 2, 3, 4 8, 9
1 = pneumonias; 2 = acute otitis media; 3 = tonsilitis; 4 = sinusitis; 5 = pyoderma; 6 = meningitis; 7 
= conjuctivitis; 8 = asthma; 9 = rhinitis; 10 = gastroenteritis with diarrhea; 11 = anemia microcytica 
hypochromica; 12 = urinary tract infection; 13 = glaucoma; 14 = periodontitis.
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manufacturer instructions. B cells were labeled with an anti-
CD20-PECy5 monoclonal antibody (BD) and T cells with 
an anti-CD3-PECy5 monoclonal antibody (BD). All stained 
cells were analyzed with a FACSCalibur flow cytometer 
using the Cellquest software (BD) and the results were 
compared to those obtained with peripheral blood samples 
from 11 healthy young adults. Ten thousand events were 
acquired per sample. 
Statistical analysis
Data regarding apoptosis and B-cell number were 
analyzed statistically by the paired or unpaired one-tailed 
Student t-test. 
Results
Concentration of serum and salivary immunoglobulins 
Normal or elevated serum IgG levels were observed in 
RTS patients (see Figure 2). Compared to normal values 
Figure 2. Serum IgG levels of patients with Rubinstein-Taybi syn-
drome compared to normal Brazilian references (15).
Figure 3. Subclass IgG levels of patients with Rubinstein-Taybi syndrome compared to normal Brazilian references (15). A, Serum 
subclass IgG1 levels. B, Serum subclass IgG2 levels. C, Serum subclass IgG3 levels. D, Serum subclass IgG4 levels. 
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for the Brazilian population, 7/16 had serum IgG levels 
above the 97th percentile for age, and only one had IgG 
levels higher than 2000 mg/dL. In 10 of the 16 RTS patients 
studied, IgG1 levels were higher than the 97th percentile 
(see Figure 3A). Only one patient had serum IgG2 below 
the 3rd percentile (see Figure 3B). All patients had serum 
IgG3 levels within normal values and 6/15 had serum IgG4 
levels higher than the 97th percentile (see Figure 3C). We 
measured the levels of antibody IgA in salivary and serum 
samples from RTS patients. All patients evaluated presented 
normal salivary and serum IgA levels (see Figure 4A and 
B). Fifteen RTS patients had serum IgM levels above the 
97th percentile, and 14/16 had IgM levels higher than 200 
mg/dL, even in the absence of clinical signs of infection 
(see Figure 5). 
Anti-ABO titers
We determined the titers of anti-ABO IgM antibodies in 
serum of RTS patients and of healthy control individuals 
in parallel. Most patients presented 64-1 to 128-1 anti-ABO 
IgM antibody titers. The anti-ABO IgM antibody titers of the 
RTS patients were equivalent to those of the healthy control 
individuals (data not shown). 
Anti-tetanus toxoid IgG antibody titers
In 50% of the patients, the levels of IgG antibodies were 
considered to be protective and 50% responded after a 
booster tetanus toxoid dose (data not shown).
Serum concentrations of pre- and post-immunization 
anti-pneumococcal IgG and IgM antibodies
All RTS patients showed significantly higher post-immu-
nization anti-pneumococcal IgG antibody levels compared 
to the pre-immunization levels of the serotypes evaluated. 
Serotypes 1 and 14 were 4-fold higher in all patients, even 
in the IgG2-deficient patient 1. All patients had post-vaccine 
levels of anti-pneumococcal IgG equal to or higher than 1.3 
mg/mL for the majority of the vaccine serotypes evaluated 
(see Table 2). The pre-immunization anti-pneumococcal 
IgM antibody levels for serotypes 1, 5, 6B, 9V, and 14 were 
higher in 12 RTS patients (see Table 3). 
Absolute numbers of total B cells and B-cell subsets 
in peripheral blood 
Flow cytometry analysis revealed significantly higher 
absolute numbers of total B cells (CD20+CD45+), naive B 
cells (CD20+CD27-), memory B cells (CD20+CD27+), B1 
subset cells (CD20+CD5+) and cell surface immunoglobulin 
M (sIgM+) B cells in the peripheral blood of RTS patients 
compared to healthy controls (see Figure 6A). 
In percentile terms, there were significant differences 
only in the population of B1 subsets and sIgM+ B cells of 
the patients (data not shown). The other subpopulations of 
B cells did not present significant differences in percentile 
values compared to healthy controls (data not shown). 
Figure 4. Salivary (A) and serum (B) IgA levels of patients with 
Rubinstein-Taybi syndrome (RTS) compared to normal Brazilian 
references (15). Note: of the 16 RTS patients evaluated, only 9 
showed up to the lab for saliva collection.
Figure 5. Serum IgM levels of patients with Rubinstein-Taybi syn-
drome compared to normal Brazilian references (27).
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Percentile values of apoptosis in total 
leukocytes and B cells in peripheral 
blood
We perfomed the evaluation of apoptosis 
in only 11 of the 16 RTS patients because 
5 did not appear for collection of blood 
samples. Nine of these 11 RTS patients 
presented higher percentages of apoptotic 
cells in peripheral blood samples compared 
to healthy controls, in determinations run 
in parallel. A higher rate of apoptosis was 
observed in the population of B cells in 9 of 
the 11 RTS patients evaluated (see Figure 
6B), whereas 2 RTS patients were similar to 
control subjects (analysis run in parallel). 
Discussion
Regarding the humoral immune re-
sponse, the main findings in RTS patients 
were high concentrations of serum IgM and 
IgG1 subclasses compared to individual 
healthy controls, according to age group 
and in the absence of clinical signs of in-
fection. Only one patient had serum IgG2 
below the 3rd percentile. Freitas et al. (13) 
described another Brazilian patient with RTS 
with periodontal diseases and recurrent 
respiratory infections and with high levels 
of serum total IgM. Xu et al. (18) measured 
immunoglobulin levels in mice in which they 
had induced inactivation of the CBP or p300 
alleles. The mice with CBP inactivation had 
2-fold higher IgG3 and IgM levels compared 
to controls, whereas the mice with p300 
inactivation had normal amounts of IgG3 
and IgM (18). In murine models, the loss 
of CBP in B cells leads to higher levels of 
IgG3 and IgM (18). These findings suggest 
that the serum concentration of IgM can 
be regulated by activation of CREB protein 
when it is phosphorylated by protein kinase A 
and interacts with the KIX region of CBP (19-
21). Immunophenotyping of B cells showed 
that the absolute numbers of naive B cells 
(CD20+CD27-), total B cells (CD20+CD45+) 
and memory B cells (CD27+CD45+) were 
higher in all of our RTS patients. B1 subsets 
(CD20+CD5+) and sIgM+ B lymphocytes 
were higher both in percent and in absolute 
number. We demonstrated here that differ-
ences in the expression of the total B cells 
and their subpopulations (naive, memory, 
B1, and sIgM+ B cells) were statistically 
significant (P < 0.005) between RTS patients 
Table 2. Response to immunization with the 23-valent pneumococcal polysaccha-
ride vaccine: pre-immunization and post-immunization pneumococcal antibody ti-
ters in patients with Rubinstein-Taybi syndrome. 
Serotype and antibody titer
1 3 4 5 6B 9V 14 18C 19F 23F
Patient 1
Pre 0.4 1.0 0.4 0.5 0.7 1.7 1.7 0.6 1.1 0.6
Post 9.4 1.4 10.3 0.8 3.0 8.9 23.1 4.2 4.9 1.5
Patient 2
Pre 5.0 3.3 6.1 2.5 3.9 1.2 2.5 2.2 10.8 2.5
Post 43.0 3.2 7.9 11.4 6.0 >50.0 14.5 4.2 33.7 5.0
Patient 3
Pre 2.6 2.8 2.4 5.7 5.7 3.1 3.8 1.9 7.3 4.6
Post 31.0 5.9 7.0 46.4 12.9 6.0 26.1 10.7 8.4 4.9
Patient 4
Pre 2.6 2.8 4.0 4.6 2.7 6.4 7.8 1.6 12.1 6.6
Post 31.0 5.9 9.6 9.9 14.8 20.7 19.2 6.1 24.3 8.5
Patient 5
Pre 3.3 0.8 0.8 0.8 1.7 0.8 1.7 1.6 5.1 2.5
Post 8.2 1.0 3.3 8.2 3.1 3.9 4.6 5.8 21.5 2.9
Patient 6
Pre 0.5 0.9 0.2 1.9 0.8 0.5 1.9 0.3 1.1 0.5
Post >50.0 1.6 4.5 8.1 1.7 4.6 >50.0 3.9 10.5 5.8
Patient 7
Pre 0.5 0.9 0.3 0.6 5.5 0.7 1.5 0.5 1.4 1.4
Post 6.6 2.9 2.0 2.5 6.4 2.9 9.4 5.1 5.5 2.6
Patient 8
Pre 0.6 1.9 5.5 0.7 3.2 0.4 1.8 0.4 1.6 0.8
Post 3.8 3.0 4.8 3.8 3.8 8.8 2.1 2.6 2.7 0.9
Patient 9
Pre 0.6 0.9 0.5 0.9 0.8 0.4 1.3 0.4 1.9 0.9
Post 10.0 2.2 1.6 1.3 1.4 14.5 25.3 2.6 2.5 1.4
Patient 10
Pre 0.7 1.2 0.5 1.2 0.8 6.3 3.4 0.4 1.8 0.9
Post 2.9 1.6 1.5 1.9 0.8 5.9 21.6 1.3 2.7 1.2
Patient 11
Pre 1.1 3.5 0.5 1.0 1.0 0.6 2.5 11.3 1.9 1.0
Post 5.4 4.8 1.8 2.5 0.8 9.7 7.2 9.9 2.9 1.0
Patient 12
Pre     # # #   #  #    #    # # # #
Post 4.3 0.6 # 1.3 0.3 4.2 2.8 # # #
Patient 13
Pre 0.4 0.5 # 0.2 0.2 0.1 0.8 # # #
Post 11.2 1.6 # 2.4 0.4 16.8 5.5 # # #
Patient 14
Pre 1.4 1.2 # 1.2 5.3 1.0 1.2 # # #
Post 2.6 3.8 # 1.6 2.3 1.6 5.6 # # #
Patient 15
Pre 1.1 0.5 # 0.6 0.4 2.9 0.7 # # #
Post 5.7 4.5 # 5.2 17.2 12.7 49.4 # # #
Patient 16
Pre 1.8 1.6 # 0.5 0.7 6.5 1.7 # # #
Post 2.5 5.4 # 3.4 4.2 14.1 7.3 # # #
Post-immunization levels ≥1.3 mg/mL or a 4-fold increase of baseline value arbi-
trarily defined according to references 16 and 17. #Serum samples were insufficient 
for the determination of antibody titers.
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Figure 6. A, Flow cytometry analysis of the absolute number 
of total, subsets and sIgM+ B lymphocytes in peripheral blood 
samples from patients with Rubinstein-Taybi syndrome (RTS; N 
= 16) compared to healthy controls (N = 16). B, High percentage 
of apoptosis in the total leukocytes and B cells of RTS patients (N 
= 11) compared to healthy controls (N = 11). Data are reported as 
means ± SD. P = RTS patients; C = healthy controls; sIgM = cel-
lular surface immunoglobulin M. *P < 0.005, compared to healthy 
controls (Student t-test).
Table 3. Pre-immunization and post-immunization anti-pneumo-
coccal IgM antibody levels (mg/mL) for the different serotypes (1, 
5, 6B, 9V, and 14). 
Serotype and antibody titer
1 5 6B 9V 14
Patient 1
Pre 5.0 12.3 10.5 5.9 5.1
Post 5.7 13.8 11.0 5.2 5.3
Patient 2
Pre 3.0 5.6 4.8 2.4 2.8
Post 14.1 10.5 7.4 9.9 4.2
Patient 3
Pre 3.7 7.6 6.4 3.2 4.5
Post 4.7 10.9 6.6 5.2 5.2
Patient 4
Pre 1.0 2.6 1.9 1.3 1.1
Post 2.8 4.7 2.4 4.3 1.2
Patient 5
Pre 1.8 3.7 2.9 1.8 2.0
Post 5.7 8.1 3.9 4.5 3.2
Patient 6
Pre 2.4 6.1 5.9 2.2 2.8
Post 3.2 6.4 4.4 3.4 3.3
Patient 7
Pre 1.8 4.5 3.8 1.9 2.0
Post 2.6 5.5 4.6 2.5 2.2
Patient 8
Pre 1.7 4.2 3.6 1.8 2.1
Post 2.5 5.4 4.5 4.3 3.2
Patient 9
Pre 5.3 13.2 11.1 6.4 6.3
Post 7.5 18.9 14.6 8.7 10.9
Patient 10
Pre 6.2 14.7 11.2 6.0 4.4
Post 7.6 19.8 14.2 12.3 5.7
Patient 11
Pre 3.9 8.2 6.3 3.2 3.7
Post 5.3 10.9 6.0 7.5 4.6
Patient 12
Pre 3.6 4.0 3.6 3.8 4.2
Post 3.7 4.8 4.1 3.7 5.7
Patient 13
Pre 2.5 2.4 3.6 4.2 2.9
Post 3.5 3.3 4.4 4.8 3.3
Patient 14
Pre 2.0 1.8 2.6 2.9 2.3
Post 2.6 2.9 2.4 2.6 2.4
Patient 15
Pre 2.0 1.9 2.7 2.8 2.4
Post 2.6 3.5 3.3 3.1 3.0
Patient 16
Pre 1.1 1.1 1.5 1.5 1.2
Post 1.1 1.2 1.5 1.7 1.4
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and control subjects. These findings suggest that the lym-
phocytosis detected in patients predominantly involves B 
lymphocytes. Based on the literature, we know that both 
CBP and p300 genes are essential to maintain B-cell ho-
meostasis in peripheral blood and that CBP, in particular, is 
involved in the normal differentiation of these cells (22,23). 
In 45-56% of patients with RTS, there is association with 
mutations of the CREBBP gene (7). Genetic analyses of 
the 16 RTS patients in the present study are in progress. 
Preliminary data have demonstrated mutation or deletion 
in the CBP gene in 7 of the 16 RTS patients.
The patients studied here, had presented recurrent 
respiratory infections mainly in the first decade of life. 
All RTS patients presented post-vaccinal levels of anti-
polysaccharide pneumococcal IgG considered to be pro-
tective against most of the 10 serotypes of the 23-valent 
pneumococcal vaccine tested. The protective antibody 
responses to polysaccharides observed in our study are 
in contrast to the findings of Naimi et al. (24) who showed 
a defective anti-polysaccharide antibody response in three 
RTS patients. Our results showed that RTS patients did not 
present defects in the production of antibodies against both 
T-dependent (anti-tetanus toxoid IgG) and T-independent 
(anti-pneumococcal IgG) antigens. 
The recurrent respiratory infections of our RTS patients 
were responsive to penicillin derivatives and were most 
probably caused by encapsulated bacteria, mainly pneumo-
cocci. Antibodies are well known to be critical for protective 
immunity against pneumococcal infections (25). How can we 
explain a normal antibody response of our RTS patients to 
pneumococcal polysaccharides despite their susceptibility 
to respiratory bacterial infections? One possibility is a defect 
in the activation of NF-κB by CBP. Some investigators have 
suggested that recruitment of CBP to p65-containing NF-κB 
complexes is essential for transcriptional activity, and that 
this interaction between p65 and CBP is a prerequisite for 
efficient transcription by NF-κB (19-21). 
Our RTS patients also had a reduction of infectious 
episodes with age and they did not present quantitative 
deficiencies in immunoglobulin levels, or in specific antibody 
production to both polysaccharide and protein antigens, or in 
the percent and the absolute number of B cells. In addition 
to the importance of the CBP gene for the transcriptional 
activity of NF-kB, the hypothesis exists that the loss of CBP 
in patients with RTS can interfere with a complete activation 
of NF-kB and thus impair the immune response directed 
against extracellular pathogens that are dependent on the 
pathway of NF-kB transcription. Another possible explana-
tion of the recurrent respiratory infections by extracellular 
bacteria that infected our patients even in the presence of 
protective levels of specific antibodies would be that the 
production of anti-IgG pneumococcal polysaccharides is not 
effective in eliminating the pathogen due to low avidity of 
these antibodies for the antigen. This involves the maturation 
of the affinity of antibodies for antigens that occurs through 
cellular signaling by costimulatory molecules and also by 
the action of cytokines from the interaction of activated T 
and B lymphocytes. 
Our results demonstrated a persistent leukocytosis in 
RTS patients even in the absence of clinical signs of in-
fection (11,000 to 26,000/mm3) in 12 of 16 subjects (data 
not shown). To determine whether the cause of persistent 
leukocytosis was linked to defects in the intrinsic pathway 
of cellular apoptosis in RTS patients, we determined the 
rate of apoptosis in their peripheral blood and detected a 
higher percentage of apoptosis in total leukocytes and B 
cells of 9 of 11 RTS patients compared to healthy controls. 
Studies in murine models suggest that the high percent-
age of B-cell apoptosis in our patients with RTS is due to 
decreased expression of protein BCL-2 by these cells. 
BCL-2 is the first member of the family of five anti-apoptotic 
proteins (BCL-2, BCL-XL, BfL-1, and McL-1) that resides in 
the mitochondria and in the endoplasmic reticulum. Some 
investigators have shown that the CREBBP gene functions 
as an important factor for survival and protection against 
cellular apoptosis (26,27). In transgenic mice that express 
a dominant-negative CREB construct, there was higher 
apoptosis after activation of these cells (26,27). Reduced 
levels of BCL-2 protein were observed in the B lymphocytes 
of these transgenic mice (23,27).
Xiang et al. (28) have shown that mutations in CREB 
result in significantly reduced protein levels and gene 
expression of BCL-2 in B lymphocytes, and BCL-2 is es-
sential for the survival of B cells. Thus, CREB is essential 
for basal expression of BCL-2 and to increase the BCL-2 
levels after activation of B cells (28). Wilson et al. (29) have 
demonstrated that CREB is an important transcription fac-
tor of gene BCL-2 in B cells, and that after the activation 
of these cells, CREB interacts with the BCL-2 promoter, 
enabling the gene expression of BCL-2, which culminates 
in the protection of the cells from apoptosis. How to explain 
the persistent leukocytosis (lymphocytosis) with the high 
rate of apoptosis of total leukocytes and B lymphocytes 
observed in patients with RTS? We know that BCL-2 has 
an important role in saving the cells from apoptosis, but 
also in inhibiting cell proliferation. Thus, reduced BCL-2 
levels promote an increase of apoptosis and also of cell 
proliferation (leukocytosis - lymphocytosis). Some investiga-
tors have shown that BCL-2 can inhibit apoptosis and cell 
proliferation by regulating the expression of another gene 
called c-MYC (30). We hypothesized that the patients with 
RTS had reduced levels of Bcl-2, promoting an increased 
percentage of apoptosis and of cellular proliferation.
When evaluating the humoral immune response of 16 
RTS patients, we demonstrated that most had normal levels 
of total serum IgG, IgG2 subclass and anti-polysaccharide 
IgG antibodies. However, they presented high IgM and 
IgG1 concentrations. The only patient with low IgG2 levels 
presented a normal anti-polysaccharide antibody response. 
We do not consider this patient to have antibody deficiency. 
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Despite an apparently normal humoral immunity, the pa-
tients presented recurrent respiratory infections caused by 
extracellular bacteria. 
In conclusion, the RTS patients evaluated in the pres-
ent study did not show deficiency of the humoral immune 
response. However, our findings showed signs of B cell 
dysregulation in these patients. Further investigation of 
the cellular and molecular mechanisms involved in the im-
mune response and in the regulation of B-cell apoptosis 
are necessary to clarify the alterations observed in the 
affected patients. 
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